Clinical Trial Update: The Risk of Cancer in Users of Regranex (Becaplermin) and Matched Comparators (Nonusers of Regranex [Becaplermin])

View source ↗

Summary

A completed clinical trial update evaluating whether use of becaplermin (Regranex) in diabetes patients is associated with cancer risk, compared with nonusers.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diabetes Mellitus

Drugs mentioned

• Regranex (becaplermin)

Snippet

Sponsor: Ethicon, Inc. | Conditions: Diabetes Mellitus | Status: COMPLETED